TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

Go back to TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
TG THERAP (NASDAQ: TGTX) Delayed: 53.07 -0.13 (0.24%)
Previous Close $53.20    52 Week High $14.87 
Open $53.02    52 Week Low $4.90 
Day High $53.70    P/E N/A 
Day Low $52.53    EPS $-0.67 
Volume 802,242